BRISBANE, Calif., Nov. 8 /PRNewswire-FirstCall/ -- InterMune, Inc. announced today multiple presentations scheduled to take place in scientific sessions at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held November 11 - 15, 2005 at the Moscone West Convention Center in San Francisco, CA.
Monday, November 14, 2005 Poster Pres #869: 8:00 a.m. - 6:30 p.m. Seiwert, Scott, et al. ITMN A and B, Novel Inhibitors of the HCV NS3/4 Protease Retain Their Potency Against VX-950 and BILN-2016 Resistant NS3/4 Protease Mutants and an IFN-alpha-2a Resistant HCV Replicon Poster Pres #851: 8:00 a.m. - 6:30 p.m. Sjogren, Maria, et al. Sustained Virologic Response Rates from a Randomized Trial of HCV Genotype-1 Subjects Treated with Either Consensus IFN and Ribavirin or Pegylated Interferon alfa-2b and Ribavirin Poster Pres #872: 8:00 a.m. - 6:30 p.m. Tan, Hua, et al. An alpha-glucosidase Inhibitor Approved for Use in Type II Diabetes Has Antiviral Activity and Displays Synergy with IFN alfacon-1 in a Surrogate System for HCV Tuesday, November 15, 2005 Poster Pres #1268: 8:00 a.m. - 12:30 p.m. Leevy, Carroll, et al. Sustained Virologic Response (SVR) to Retreatment with IFN alfacon 1 + Ribavirin in HCV/HIV Coinfected Patients Who Had Failed 12 weeks of PEG IFN alpha 2 + Ribavirin Therapy Poster Pres #1267: 8:00 a.m. - 12:30 p.m. Leevy, Carroll, et al. Comparison of African American and Non-African American Patient Sustained Virologic Response in PEG-IFN Alpha 2 + Weight-Based Ribavirin Nonresponders Retreated with IFN alfacon-1 + IFN gamma- 1b Poster Pres #1179: 8:00 a.m. - 12:30 p.m. Huang, Ying, et al. Analysis of Responses to Alpha and Gamma Interferons in Hepatitis C Virus Infected Chimpanzees Poster Pres #1328: 8:00 a.m. - 12:30 p.m. Tong, Myron, et al. Viral Factors which Predicted Liver-Related Deaths and Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B About Infergen(R)
Infergen(R) is a bio-optimized type 1 interferon alpha indicated for treatment of adult patients with chronic HCV infections with compensated liver disease and is approved for three times-per-week dosing. Infergen(R) is the only interferon alpha with data in its label regarding use in patients following relapse or non-response to certain previous treatments. The most common side effects are flu-like symptoms (i.e., headache, fatigue, fever, myalgia, and rigors). Physicians and patients can obtain additional prescribing information regarding Infergen(R), including the product’s label, safety profile and the black box warning for all interferon alphas regarding neuropsychiatric, autoimmune, ischemic and infectious disorders, by visiting www.infergen.com.
About Actimmune(R)
Interferon gamma is a naturally occurring protein that stimulates the immune system. InterMune markets Actimmune(R) for the treatment of two life- threatening congenital diseases: chronic granulomatous disease and severe, malignant osteopetrosis. The most common side effects are flu-like symptoms, including headache, fatigue, fever, rash, and chills. InterMune is conducting two late-stage trials of Actimmune(R): the INSPIRE Trial, a Phase III study of interferon gamma-1b in IPF, and the GRACES Trial, a Phase III study of interferon gamma-1b in ovarian cancer. InterMune was recently granted two composition of matter patents related to Actimmune(R) in the United States, extending its patent protection until 2022. Physicians and patients can obtain additional prescribing information regarding Actimmune(R), including the product’s safety profile, by visiting www.actimmune.com.
About InterMune
InterMune is a biopharmaceutical company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a broad and deep late-stage product portfolio addressing IPF and hepatitis C virus infections, particularly nonresponders, or those patients who do not respond to first-line therapy. The pulmonology portfolio includes Actimmune(R) and pirfenidone. Actimmune(R) is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF. Pirfenidone is also being developed for the treatment of IPF. In addition to three-times-a-week Infergen(R), a currently marketed product indicated for the treatment of chronic HCV infections, the hepatology portfolio includes the DIRECT Trial, a Phase III study of daily Infergen(R) plus ribavirin in non- responders. Additionally, InterMune is developing a pre-clinical stage small molecule program targeted at the HCV protease. For additional information about InterMune and its development pipeline, please visit www.intermune.com.
Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to product development. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward- looking statements or information. InterMune’s actual results could differ materially from those described in InterMune’s forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading “Risk Factors” in InterMune’s quarterly report on Form 10-Q filed with the SEC on November 7, 2005 (the “Form 10-Q”) and other periodic reports filed with the SEC, including the following: (i) risks related to the development of our products and product candidates; (ii) risks related to government regulation and approval of our products and product candidates; (iii) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (iv) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (v) risks related to achieving positive clinical trial results; and (vi) risks related to timely patient enrollment and retention in clinical trials. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-Q and InterMune’s other periodic reports filed with the SEC.
InterMune, Inc.
CONTACT: Investors, Judy Hayes of InterMune, Inc., +1-415-466-2242, orir@intermune.com; or Media, Pam Lord of Atkins + Associates,+1-858-527-3494, or plord@irpr.com, for InterMune, Inc.
Web site: http://www.intermune.com/
